HLA Class III: A susceptibility region to systemic lupus erythematosus in Tunisian population

Hend Hachicha¹,²,³*, Nadia Mahfoudh⁴, Hajer Fourati², Nesrine Elloumi², Sameh Marzouk⁵, Sawsan Feki¹,², Raouia Fakhfakh⁵, Faten Frikha⁵, Abir Ayadi², Amira Maatoug², Liia Gaddour⁴, Feiza Hakim⁴, Zouheir Bahloul⁵, Hafedh Makni³, Hatem Masmoudi¹,², Arwa Kammoun⁴

¹ Immunology Department, Habib Bourguiba University Hospital, Sfax, Tunisia, ² UR12SP14, Habib Bourguiba University Hospital, Sfax, Tunisia, ³ Faculty of Medicine of Sfax, University, Sfax, Tunisia, ⁴ Histocompatibility Department, Hedi Chaker University Hospital, Sfax, Tunisia, ⁵ Internal Medicine Department, Hedi Chaker University Hospital of Sfax, Sfax, Tunisia

* hendhachicha@yahoo.fr

Abstract

Background and objectives

Short tandem repeats (STR) are usually used as informative polymorphic markers for genetic mapping and for disease susceptibility analysis. The involvement of these microsatellite markers localized in the MHC region was reported in many auto-immune diseases.

In this study we analyzed for the first time eight polymorphisms of microsatellite loci at the HLA region: D6S291, D6S273, TNFa, b and c, MICA, D6S265 and D6S276, in Tunisian systemic lupus erythematosus (SLE) patients.

Materials and methods

We performed a case control study in which the microsatellite loci were amplified using specific primers labeled with NED, VIC, PET or 6-FAM and analyzed using GeneScan software 3.7. For the statistical analysis, we used SPSS software and we performed a sub-haplotype scoring test using the haplo.stats software developed in the R language.

Results

We found that two mean associated regions existed; the most statistically significant encompassed the 3 TNF markers (p = 0.0003, OR = 19.34); the latter covered the DR region. In fact, when scoring haplotypes in 3 marker-sliding windows, the p value increased as we moved away from the TNF region and decreased again when we approached the DRB1 locus. We also established for the first time the negative association between alleles of D6S291 and SLE. The majority of clinical and serological correlations were noted with TNF alleles.
Conclusion
Our results confirm the association between TNF and DRB1 polymorphisms and SLE. The association between alleles of D6S291 and SLE needs however to be verified by the analysis of other markers beyond this region.

1. Introduction
The chromosomal region including the human leukocyte antigen (HLA) Class II to Class I genes has been implicated in susceptibility to systemic lupus erythematosus (SLE) and other autoimmune diseases such as rheumatoid arthritis, insulin-dependent diabetes mellitus, pemphigus foliaceus, and Gougerot Sjögren’s syndrome [1–2–3]. This region situated on the short arm of chromosome six encodes several molecules: HLA Class I and Class II implicated in the presentation of peptides to the immune cells which is an essential phenomenon for the production of auto-antibodies characterizing auto-immune diseases; it also encodes other proteins suggested to be implicated in the physiopathology of this kind of diseases for instance complement fractions and TNF[4].

In SLE, the strongest genetic association described so far, has been with the HLA class II alleles. Thus, susceptibility to SLE has been correlated specially with HLA-DRB1 and HLA-DQB1 alleles in different ethnic groups [5–6]. In our population, we demonstrated a predisposition factor effect of HLA DRB1*03 and HLA DRB1*15 for SLE[7]; this was in accordance with the majority of genetic studies.

Short tandem repeats (STR) are usually used as informative polymorphic markers for genetic mapping and for disease susceptibility analysis. The involvement of these microsatellite markers localized in the MHC region was reported in many auto-immune diseases[2, 8,9]. Several data have reported the association of HLA microsatellite with SLE[10].

In this study we analyzed eight polymorphisms of microsatellite loci at 6p21.3–21.4 spanning HLA region: D6S291, D6S273, TNFa, b and c, major histocompatibility complex class I chain-related gene A (MICA), D6S265 and D6S276, in 87 SLE patients compared to 123 healthy individuals recruited from the south of Tunisia and this in order to investigate any eventual new susceptibility or prognostic markers of SLE.

2. Materials and methods
2.1. Patients and controls
We performed a case /control study during five years (January 2012- January2017). This case-control study was approved by the Ethics committee of the university hospitals of Sfax, Tunisia. We recruited 210 individuals (87 patients with SLE and 123 healthy controls) originating from the South of Tunisia. Patients and controls gave their written informed consent.

Patients included in this study fulfilled the American College of Rheumatology (ACR) criteria for the diagnosis of SLE. An exhaustive information sheet containing clinical and serological features was filled for each patient.

2.2. Genotyping methods
We extracted genomic DNA from ethylene diamine tetra-acetic acid (EDTA) peripheral blood using a phenol/chloroform technique. We conducted an association study using 8
microsatellite polymorphic markers: D6S291, D6S273, TNFα, b and c, MICA, D6S265 and D6S276 covering the HLA class I, III and II regions (S1 Fig).

The microsatellite loci were amplified using specific primers (Table 1) determined from an NCBI db MHC database (http://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=mssearch) and provided by Perkin Elmer (Applied Biosystems, CA, USA). Forward primers were labeled with NED, VIC, PET or 6-FAM fluorescent labels. Amplified products were run on ABI prism 310 DNA sequencer (Perkin–Elmer, CT, USA). The output file was analyzed using GeneScan software 3.7.

2.3. Statistical study

We first compared for each marker the global alleles distribution between patients and healthy controls, using the BIGDAWG package implemented in R (https://cran.r-project.org/web/packages/BIGDAWG).

For detailed analysis, we used the Statistical Software for The Social Sciences (SPSS version 20.0, USA). We first compared STR frequencies in SLE patients and healthy controls; then we tested the impact of each allele on the different clinical and serological disease features. We searched for significant correlations using the χ² test. P values were considered as statistically significant if < 0.05. Significant p-values were corrected (pc) by the number of alleles tested for each marker (Bonferroni’s corrections) and pc < 0.05 was considered statistically significant. The odds ratio (OR) and its 95% confidence interval (CI) were calculated for each allele to estimate the magnitude of the association.

We also used binary logistic regression to assess the real contribution of STR polymorphism at the occurrence of SLE, and to see if the associations found are due to a linkage disequilibrium (LD) with HLA class II alleles already demonstrated to be associated with SLE in our population [7].

To assess the association between haplotypes and SLE, analytical approaches implemented in the software package Haplo.stats (http://cran.r-project.org/web/packages/haplo.stats) were used. The software uses an expectation-maximization algorithm to infer haplotypes from the observed genotypes with an unknown linkage phase.

In this analysis, we evaluated the association of sub-haplotypes with SLE, in a sliding window of 3 loci. Given an ordered set of markers from 1 to 8, sliding windows of overlapping

Table 1. Characteristics of studied STR.

| STR    | Localization | Repeats | Primers | Labeling |
|--------|--------------|---------|---------|----------|
| D6S291 | 6p21.2: 3.6-4cM cent DPB1 | CA | F: 5'-CTCAGAGGAATGACATGCTTAATCTAA-3' R: 5'-GGGATTACGCAATTTATCTACTACT-3' | 6-FAM- |
| D6S273 | Hsp70-Bat2 (96 kb) Tel Hsp70 | CA | F: 5'-GCAACTTTTCTGTCAATCATGCACT-3' R: 5'-AAAACAAAAATAATTTTCTTG-3' | 6-FAM- |
| TNFc  | Intron of TNFB | TC | F: 5'-GGCTTTCCTGATCAGCTCATATGTC-3' R: 5'-TATTTATGATGAGCGGAGAG-3' | PET |
| TNFa  | 6p21.3 Tel (3.5 kb)/TNF B | AC | F: 5'-GCCTCTAGATTTTCAGGCAGCC-3' R: 5'-CCTTTCCTCCCTGAAACACAC-3' | VIC |
| TNFb  | 6p21.3 Tel. (3.5 kb)/TNF B | TC | F: 5'-GACTCCAGAGGAGGACGAGA-3' R: 5'-GTGGTGTGACCAAGGGAGGAGA-3' | VIC |
| MICA  | 40 Kb cent to HLA-B | GCT | F: 5'-CCTTTCCTCTCTCCGGAAATGC-3' R: 5'-ATCGGTAACACAGCAAAACTGC-3' | NED |
| D6S265 | HLA-E/HLA-A | CA | F: 5'-ACGTTGCTACCCATTTACCT-3' R: 5'-ATCGAGTAAAACACAGCAAAACTGC-3' | NED |
| D6S276 | Tel (6500 kb) HLA-A | CA | F: 5'-GAAATCAATTCACCTCCCGAAG-3' R: 5'-GGGTTGCACTTGTTCCCTCCT-3' | VIC |

https://doi.org/10.1371/journal.pone.0198549.t001
haplotypes are tested in sequence, thereby markers 1–2–3 are treated as a single haplotype, then markers 2–3–4 are treated as a single haplotype, then markers 3–4–5, etc.

Sub-haplotype analysis included DRB1* and DQB1* loci reported in our previous study [7].

3. Results

3.1. Demographic, clinical and serological characteristics

The age in our SLE patients ranged from 14 to 90 years (mean age = 32.11 ± 13.57). The sex ratio female patients to male patients (F/M) was 6.9 (Table 2). The control group was formed by 72 women and 51 men. Their average age was 32 years ± 9.28.

3.2. HLA microsatellites alleles

Microsatellite allele distributions were different in patients and controls. The difference was significant for 2 loci: TNFc (p = 10\(^{-6}\)) and D6S291 (p = 0.045) (Table 3).

According to the repetition number pattern, TNFb4 was significantly more frequent in patients than in HC, TNFc1 was also positively associated with SLE while TNFc2 was identified to be negatively associated with the disease (p < 10\(^{-5}\), OR = 0.24). (Table 3)

After logistic regression all these markers remained associated with p value = 0.04 for TNFc1; 0.001 for TNFb4.

3.3. Clinical and serological associations with STR alleles

The majority of clinical and serological correlations were noted with TNF alleles (Table 4).

Patients with lupus nephritis expressed TNFb4 and TNFa11 more than patient without LN. The TNFc2 allele was negatively associated with the production of anti-Sm and anti-cardiolipin antibodies, however this allele, was more frequent in patients producing rheumatoid factors. (Table 4)

3.4. Haplotype analysis

The three- marker window covering the TNF region showed the strongest association with SLE in this study. Seven haplotypes were significantly increased in patients. After Bonferroni’s correction, four haplotypes lost their association with the disease (Table 5).

When we included DR DQ HLA class II alleles in the analysis[7], we noted the existence of 2 associated regions. The most statistically significant encompassed the 3TNF markers; the latter covered the DR region (S2 Fig).

4. Discussion

Microsatellites in the HLA region are reported to be of particular interest in the susceptibility and pathogenesis of different immune mediated diseases[11–12]. As for systemic lupus erythematosus, no studies have been carried out in North African Lupus patients concerning HLA microsatellite markers.

We investigated in this study 8 STR covering the whole HLA region. D6S276 marker is telomeric to the class I region, and was found to be associated with numerous inflammatory diseases. D6S276 microsatellite is associated with pemphigus foliaceus in the Tunisian population [2]. In accordance with Shai et al [13], no significant difference could be established in D6S276 alleles distribution in our SLE patients when compared with healthy controls.

D6S265 marker also situated in HLA class I region does not seem to be implicated in SLE in our patients since the association found disappeared after Bonferroni’s correction (p = 0.02; pc = 0.26). This result was also reported by Smerdel-Ramoya et al [10].
The third marker, located within the MHC class I region, was MHC class I chain-related genes (MIC). In previous studies sequence analysis of the MIC-A gene showed a trinucleotide repeat (GCT) microsatellite polymorphism within the trans-membrane region. So far, seven alleles of the exon 5 of the MIC-A gene, which consist of 4, 5, 6, 8, 9 and 10 repetitions of GCT, or five repetitions of GCT with an additional nucleotide insertion (GGCT), have been identified. Recent works support the findings that MIC-A is associated with several autoimmune diseases [14].

In our study we tried to elucidate the role of MICA microsatellite polymorphism in SLE development. In accord with a Spanish case control study [15], we have found significant decrease of frequencies of the MICA-A5 allele in SLE patients. This allele was however reported to be predisposing to lupus in the Italian population [16]. The positive associations with MICA-A5.1 illustrated in these two studies did not appear in ours. MICA-A9 and MICA-A6 were reported to be protective in Italians and in Czechs respectively [16–17].

### Table 2. Clinical and immunological manifestations in our patients.

|                  | Number | Frequency% | Availability |
|------------------|--------|------------|--------------|
| Sex F/M          | 76/11  |            |              |
| Clinical manifestations |        |            |              |
| Malar rush       | 41     | 51.9       | 90.8         |
| Photosensitivity | 36     | 45.6       | 90.8         |
| Buccal ulceration| 11     | 13.9       | 90.8         |
| Anemia           | 66     | 48.6       | 89.7         |
| Arthritis        | 18     | 22.8       | 90.8         |
| Polyalgia        | 51     | 64.6       | 90.8         |
| Lupus nephritis  | 38     | 48.1       | 90.8         |
| Pericarditis     | 19     | 24.1       | 90.8         |
| Pleurisy         | 12     | 15.2       | 90.8         |
| Raynaud’s syndrome | 6      | 7.6        | 90.8         |
| Thrombosis       | 13     | 17.1       | 87.4         |
| Neurologic disorders | 12    | 16.2       | 85.1         |
| Serology         |        |            |              |
| Anti-dsDNA       | 60     | 70.6       | 97.7         |
| Anti-nucleosome  | 51     | 60.7       | 96.6         |
| Anti-Sm          | 25     | 29.8       | 96.6         |
| Anti-RNP         | 25     | 29.8       | 96.6         |
| Anti-SSA         | 48     | 57.1       | 96.6         |
| Anti-SSB         | 20     | 23.8       | 96.6         |
| Anti-Ribosome    | 16     | 19         | 96.6         |
| Anti-Histone     | 27     | 32.1       | 96.6         |
| Anti RO52        | 31     | 36.9       | 96.6         |
| Low CH50         | 36     | 60         | 69           |
| Low C3           | 31     | 46.3       | 77           |
| Low C4           | 34     | 50.7       | 77           |
| Anti-cardiolipin | 42     | 60         | 80.5         |
| Anti-β2gp1       | 23     | 35.9       | 73.6         |
| Rheumatoid factors | 14    | 24.6       | 65.5         |

F: female, M: male.

[https://doi.org/10.1371/journal.pone.0198549.t002](https://doi.org/10.1371/journal.pone.0198549.t002)
negative associations have not been reported by others. In our study there were no statistic differences between patients and controls concerning MICA-A9 and A6.

The implication of MICA-A5 in the susceptibility of SLE can be explained by the findings of Yoshida et al. These researchers demonstrated that MICA 129Met-A5 haplotype suppresses the expression of NKG2-D on NK cells, and thus inhibits NK cell cytotoxicity. This is consistent with previous findings showing that NK cell cytotoxicity is significantly decreased in SLE [18–19].

### Table 3. Allelic distribution of STR markers.

| Microsatellite | Allele | Frequency patients | Frequency controls | p  | pc | Odds ratio [95%CI] |
|----------------|--------|--------------------|--------------------|----|----|-------------------|
| D6S265         | 0.02   | 0.26               |                     |    |    |                   |
| MICA           | NS     |                    |                    |    |    |                   |
|                | 5      | 5.7                | 17.9               | 0.01 | 0.06 | 0.280 [0.102–0.772] |
| TNFβ           | 0.009  | 0.063              |                    |    |    |                   |
|                | 4      | 55.2               | 32.5               | 0.001 | 0.007 | 2.554 [1.449–4.500] |
| TNFα           | 0.006  | 0.084              |                    |    |    |                   |
|                | 11     | 21.8               | 10.6               | 0.025 | 0.35 | 2.364 [1.097–5.094] |
| TNFε           | 0.000001 | 0.000002 |            |    |    |                   |
| D6S273         | NS     |                    |                    |    |    |                   |
| D6S291         | 0.005  | 0.045              |                    |    |    |                   |

NS: not significant.

p values indicated in front of the marker names correspond to the locus level analysis performed using the BIGDAWG package; pc were obtained after Bonferroni’s correction.

https://doi.org/10.1371/journal.pone.0198549.t003

### Table 4. Clinical and serological associations with STR markers.

| STR marker | Parameters(n) | Positive | Negative | P** | Odds ratio [95%CI] |
|------------|---------------|----------|----------|-----|-------------------|
| TNFβ4      | LN(79)        | 47.4%    | 68.3%    | .060 | 0.418 [0.167–0.1044] |
| TNFα11     | LN(79)        | 13.2%    | 31.7%    | .050 | 0.326 [0.104–1.028] |
| TNFε2      | Anti-Sm(84)   | 4.0%     | 30.5%    | .009* | 0.095 [0.012–0.756] |
|            | Anti-Cl(70)   | 14.3%    | 39.3%    | .017* | 0.258 [0.082–0.813] |
|            | RF(57)        | 50.0%    | 14.0%    | .005* | 6.167 [1.587–23.956] |
| TNFε HET   | Anti-Sm(84)   | 5.3%     | 36.9%    | .008* | 0.095 [0.012–0.756] |
|            | Anti-Cl(70)   | 53.8%    | 15.9%    | .005* | 6.167 [1.587–23.956] |
|            | RF(57)        | 53.8%    | 15.9%    | .005* | 6.167 [1.587–23.956] |
| MICA_5     | Anti-RO52(84) | 12.9%    | 0.0%     | .016 | 1.148 [1.003–1.315] |
| D6S265_12  | C3 (67)       | 6.5%     | 25.0%    | .052 | 0.207 [0.041–1.045] |
| D6S276_10  | Anti-β2GP1(64)| 0.0%     | 30.4%    | .026 | 0.696 [0.575–0.575] |

HET: Heterozygous genotype, LN: lupus nephritis, RF: Rheumatoid factors, Cl: cardiolipine.
n: number of patients included in each analysis
* association remained significant after Bonferroni’s correction.
** we included in this analysis significant associations or associations close to significance.

https://doi.org/10.1371/journal.pone.0198549.t004
Gupta et al have reported the association between MICA gene polymorphism and autoantibody formation in type I diabetes [20]. The present study, to our knowledge, is the first one to show the association between MICA gene polymorphism and autoantibody formation (anti-Ro52) in SLE.

As we moved away from HLA class I region and covered that coding TNF, many associations between STR markers and SLE appeared. There were significant statistical differences in frequencies of TNF microsatellite markers TNFb4, a11, c1 and c2 between patients and healthy controls (p = 0.001, 0.025, 0.003 and 0.00004 respectively). TNFb4, a11 and c1 conferred susceptibility while TNFc2 was protective. Concerning these STR, conflicting reports exist in the literature. M Van der Linden reported similar findings: the presence of TNFa1 conferred susceptibility to develop SLE in Caucasian patients [21]. Naves et al. explored 4 STR markers in the TNF (a, b, c and d) in the coding region and demonstrated, contrarily to our findings, that TNFc2 was significantly increased in SLE Spanish patients [22].

D’Alfonso et al studied 3 polymorphisms in TNF coding region -238/A, -308/A and TNFa microsatellite. They concluded that TNF region do not seem to play a role in SLE susceptibility in the Italian population [23]. Lack of TNFA-308A association with SLE was later confirmed in Caucasian SLE families [24]. A larger Caucasian study suggested that TNFA-308A association with SLE was due to its linkage disequilibrium with low gene copy number of C4A and C4B [25].

Concerning associations between STR and clinical manifestations, the most relevant were noted with lupus nephritis. Patients carrying TNFb4 and a11 developed less kidney injury compared to those without. TNF c2 was protective and prevented development of anti-Sm and anti-cardiolipine antibodies and predisposed to rheumatoid factor production.

A.H. Hajeer et al reported a positive association between SLE and microsatellite markers TNFa2, b3 and d2 alleles. These three markers were significantly associated with photosensitivity and Raynaud’s phenomenon as well as with anti-SSA antibodies production [26].

In the Greek population, TNF a11 frequencies were higher in SLE patients with renal disease and TNF a2 and b 3 frequencies in those without [27].

The last 2 STRs we investigated were D6S273 and D6S291. We found global significant difference only with D6S291. The allele 12 was negatively associated with SLE. This contrasts with the findings of Smerdel-Ramoya et al who demonstrated the association of D6S273 with SLE in the Norwegian population. Unlike D6S273, D6S291 was not associated [10].
The use of sliding window approach of three contiguous markers in the haplotype analysis allowed us, to prove that two main SLE associated regions exist in our south Tunisian population. The most statistically significant is the region containing the 3 TNF STR markers and the second one containing the DRB1\textsuperscript{a} locus. In fact, the lowest p value was found with the window containing TNF markers. Moreover, p value increased when moving away from the TNF region and decreased again when the DR marker was included.

The persistence of the significant association of D6S291 with SLE after logistic regression may be due to the existence of another associated marker beyond this STR, a hypothesis which should be investigated in further studies.

In conclusion, our results showed that specific alleles of five loci, in addition to the conventional DR/DQ, were found to be associated with SLE: D6S291, TNFa, TNFb, TNFc and D6S265. Interestingly, these findings indicate that the chromosomal region encompassing the TNF loci plays an important role in SLE probably by the induction of a high TNF production which increases inflammatory manifestations. However, more studies within other populations are necessary to evidence the general relevance of this polymorphism for SLE.

**Supporting information**

S1 Fig. Genetic map of the human MHC with microsatellites genotyped in this study. (TIF)

S2 Fig. SLE patients versus healthy controls; global p-values for sub-haplotypes in the HLA region (1: p = 0.0002; 2: p = 0.007; 3: p = 0.002; 4: p = 0.02). (TIF)

S1 Table. Characteristics of studied STR. (DOCX)

S2 Table. Clinical and immunological manifestations in our patients. (DOCX)

S3 Table. Allelic distribution of STR markers. (DOCX)

S4 Table. Clinical and serological associations with STR markers. (DOCX)

S5 Table. Three-marker window haplotype analysis. (DOCX)

**Acknowledgments**

We thank Ms. Moufida Bouyahia, proficient in the English language for proofreading the article.

This work was supported by a Grant from the “Ministère de l’enseignement supérieur et de la recherche scientifique of Tunisia”.

**Author Contributions**

**Conceptualization:** Hend Hachicha, Nadia Mahfoudh.

**Data curation:** Hajar Fourati, Nesrine Elloumi, Sameh Marzouk, Sawsan Feki, Raouia Fakhfakh, Abir Ayadi, Amira Maatoug, Lilia Gaddour, Feiza Hakim.

**Formal analysis:** Hend Hachicha, Arwa Kammoun.
Investigation: Hend Hachicha, Faten Frikha.
Methodology: Hend Hachicha.
Project administration: Arwa Kammoun.
Software: Arwa Kammoun.
Validation: Hend Hachicha, Nadia Mahfoudh, Zoeur Bahloul, Hafedh Makni, Hatem Masmoudi.
Writing – original draft: Hend Hachicha.

References
1. Arnett FC, Goldstein R, Duvic M, Reveille JD. Major histocompatibility complex genes in systemic lupus erythematosus, Sjogren’s syndrome, and polymyositis. (Review). Am J Med 85 (1988) 38–41.
2. Abida O, Mahfoudh N, Kammoun A, Gaddour L, Hakim F, Toumi A et al. Polymorphisms of HLA microsatellite marker in Tunisian pemphigus foliaceus. Hum Immunol. 74(1) (2013) 104–9. https://doi.org/10.1016/j.humimm.2012.10.013 PMID: 23073295
3. Louis E, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn’s disease (CD): influence on disease behaviour? ClinExp Immunol 119 (2000) 64–68.
4. Aringer M, Günther C, Lee-Kirsch MA. Innate immune processes in lupus erythematosus. Clin Immunol. 147(3) (2013) 216–22. https://doi.org/10.1016/j.clim.2012.11.012 PMID: 23290784
5. Castaño-Rodríguez N, Díaz-Gallo LM, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmunity Reviews. 7 (2008) 322–330 https://doi.org/10.1016/j.autrev.2007.12.002 PMID: 18295738
6. Rellea M, Weinmann-Menkea J, Scorletti E, Cavagna L, Schwartzing A. Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmunity Reviews. 14 (2015) 1005–1018 https://doi.org/10.1016/j.autrev.2015.07.003 PMID: 26164648
7. Hachicha H, Kammoun A, Mahfoudh N, Marzouk S, Feki S, Fakhfakh R, et al. HLA-DRB1*03 is associated with systemic lupus erythematosus and anti-SSB production in south Tunisia. Int J HealthSci (Qasim). 2018 Jan-Feb; 12(1):21–27
8. Barnetche T, Constantin A, Gourraud P-A, Abbal M, Garnier JG, Cantagrel A et al. Microsatellite typing of the human leucocyte antigen region: analytical approach and contribution to rheumatoid arthritis immunogenetic studies. Tissue Antigens2006; 68: 390–8. https://doi.org/10.1111/j.1399-0039.2006.00693.x PMID: 17092252
9. Pociot F, Briant L, Jongeneel CV, Mölvig J, Worsaae H, Abbal M et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23:224–31. https://doi.org/10.1002/eji.1830230135 PMID: 8093442
10. Smerdel-Ramoya A, Fiholt C, Lillevy V, Gilboe IM, Harbo HF, Maslinski S et al. Systemic lupus erythematosus and the extended major histocompatibility complex—evidence for several predisposing loci. Rheumatology (Oxford). 44(11) (2005) 1368–73.
11. Lee EY, Yim JJ, Lee HS, Lee YJ, Lee EB, Song YW. Dinucleotide repeat polymorphism in intron II of human Toll-like receptor 2 gene and susceptibility to rheumatoid arthritis. Int J Immunogenet 33(3) (2006) 211–5. https://doi.org/10.1111/j.1744-313X.2006.00599.x PMID: 16712654
12. Dalla-Costa R, Pincerati MR, Beltrame MH, Malheiro D, Petzl-Erler ML. Polymorphisms in the 2q33 and 3q21 chromosome regions including T-cell coreceptor and ligand genes may influence susceptibility to pemphigus foliaceus. Hum Immunol 71 (2010) 809–17. https://doi.org/10.1016/j.humimm.2010.04.001 PMID: 20438866
13. Shal R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ et al. “Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families.” Human Molecular Genetics 8.4 (1999): 639–644. PMID: 10072432
14. Novota P, Kolesa L, Slavcev A, Cerna M. Fluorescence based automated fragment analysis of microsatellite polymorphism within the transmembrane region of the MICA-A gene. Folia Biologica 50 (2004) 21–23 PMID: 15055739
15. Sanchez E, Torres B, Vilches JR, Lopez-Nevo MA, Ortego-Centeno N, Jimenez-Alonso J et al. No primary association of MICA polymorphism with systemic lupus erythematosus. Rheumatology. 45 (2006) 1096–1100 https://doi.org/10.1093/rheumatology/ke058 PMID: 16537577

16. Gambelunghe G, Gerli R, BartoloniBocci E, Del Sindaco P, Ghaderi M, Sanjeevi CB et al. Contribution of MHC class I chain-related A (MICA) gene polymorphism to genetic susceptibility for systemic lupus erythematosus. Rheumatology. 44 (2005) 287–292 https://doi.org/10.1093/rheumatology/keh459 PMID: 15522921

17. Fojtikova M, Novota P, Cejkova P, Pesickova S, Tegzova D and Cerna M. HLA class II, MICA and PRL gene polymorphisms: the common contribution to the systemic lupus erythematosus development in Czech population. Rheumatol Int 31 (2011) 1195–1201

18. Yoshida K, Komai K, Shiozawa K, Mashida A, Horuchi T, Tanaka Y et al. Role of the MICA Polymorphism in Systemic Lupus Erythematosus. Arthritis & Rheumatism 63(10) (2011) 3058–3066

19. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 60 (2009) 1753–63. https://doi.org/10.1002/art.24556 PMID: 19479851

20. Gupta M, Graham J, Mc Neeny B, Zarghami M, Landin-Olsson M, Hagopian WA et al. MHC class I chain-related gene-A is associated with IA2 and IAA but not GAD in Swedish type 1 diabetes mellitus. Ann N Y Acad Sci. 1079 (2006) 229–39. https://doi.org/10.1196/annals.1375.036 PMID: 17130560

21. Van Der Linden MW, Van Der Silik AR, Zanelli E, Giphart MJ, Pieterman E, Schreuder GM The et al. Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF α308A in systemic lupus erythematosus. Genes Immun. 2 (7) (2001) 373–380 https://doi.org/10.1038/sj.gene.6363794 PMID: 11704803

22. Naves M, Hajeer AH, Teh LS, Davies EJ, Ordí-Ros J, Perez-Pemón P et al. Complement C4B null allele status confers risk for systemic lupus erythematosus in a Spanish population. Eur J Immunogenet. 25 (4) (1998) 317–20. PMID: 9777334

23. D’Alfonso S, Colombi G, Della Bella S, Scorza R, Momigliano-Richiardi P. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. Tissue Antigens. 47(6) (1996) 551–5. PMID: 8813745

24. Tsuchiya N, Kawasaki A, Tsao BP, Komata T, Grossman JM, Tokunaga K. Analysis of the association of HLA-DRB1, TNFα promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test. Genes Immun. 2001 Oct; 2(6):317–22 https://doi.org/10.1038/sj.gene.6363783 PMID: 11607787

25. Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B et al. Gene Copy-Number Variation and Associated Polymorphisms of Complement Component C4 in Human Systemic Lupus Erythematosus (SLE): Low Copy Number Is a Risk Factor for and High Copy Number Is a Protective Factor Against SLE Susceptibility in European Americans Am J Hum Genet. 2007 Jun; 80(6):1037–54 https://doi.org/10.1086/518257 PMID: 17503323

26. Hajeer AH, Worthington J, Davies EJ, Hillarby MC, Poulton K, Ollier WER. TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 49 (1997) 222–227 PMID: 9098928

27. Tarass K, Carthy D, Papasteriades C, Boki K, Nikolopoulou N, Carcassi C et al. HLA-TNF haplotype heterogeneity in Greek SLE patients. Clin Exp Rheumatol. 16(1) (1998) 66–8